Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Big Pharma Frantically Plays Catch-Up

By Dave Williamson - Apr 22, 2013 at 8:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Can it still make up ground with a winning hep-c drug cocktail?

In this video, health-care analyst David Williamson discusses how Big Pharma is attempting to catch up when it comes to creating a next-gen hepatitis-C cure. Today's news features a collaboration between Merck and Bristol-Myers Squibb. Has Big Pharma missed the boat, or is there still time to get on board with a winning combination? Watch and find out.

Stocks Mentioned

$176.98 (1.75%) $3.04

Gilead Sciences, Inc.

GILD

$63.84 (0.90%) $0.57

Bristol Myers Squibb Company

$151.01 (-0.47%) $0.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Better Buy: Gingko Bioworks vs. Amyris

Have $2,000? 2 Market Crash-Ready Stocks to Buy

Stock Market Plunge: 5 Unstoppable Stocks on Sale to Buy Now and Hold Forever

2 Safe Stocks to Buy in a Bear Market

Tech Stock Sell-Off Got You Scared? Here's a Better Buy.

Motley Fool Returns

Market-beating stocks from our award-winning service.

Stock Advisor Returns

330%

S&P 500 Returns

115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Join Stock Advisor

Cumulative Growth of a $10,000 Investment in Stock Advisor

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.